Nanotechnology Now – Press Release: Arctic warming and diminishing sea ice are influencing the atmosphere: Researchers of the University of Helsinki have resolved for the first time, how the environment affects the formation of nanoparticles in the Arctic. The results give additional insight into the future of melt

Home > Press > Arctic warming and diminishing sea ice are influencing the atmosphere: Researchers of the University of Helsinki have resolved for the first time, how the environment affects the formation of nanoparticles in the Arctic. The results give additional insight into the future of meltMeasurements in Northern Greenland ...

Nanotechnology Now – Press Release: Threads that sense how and when you move? New technology makes it possible: Engineers created thread sensors that can be attached to skin to measure movement in real time, with potential implications for tracking health and performance

Home > Press > Threads that sense how and when you move? New technology makes it possible: Engineers created thread sensors that can be attached to skin to measure movement in real time, with potential implications for tracking health and performanceScanning electron microscopy of carbon ink-coated threads. Straight thread on...

Shuffling bubbles reveal how liquid foams evolve

Feb 06, 2021 (Nanowerk News) Researchers from Tokyo Metropolitan University studied the dynamics of foams. When a drop of water was added to a foam raft, the bubbles rearranged themselves to reach a new stable state. The team found that bubble movement was qualitatively different depending on the range of...

Nanotechnology Now – Press Release: Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

Home > Press > Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed DyslipidemiaAbstract:Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study...